Irish life sciences company Malin Corporation has acquired 33% stake in Wren Therapeutics with the aim of developing rational therapeutic strategies.

The target company is a UK-based biopharmaceutical organisation that is a spin out from the University of Cambridge, UK, and Lund University, Sweden.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

"The acquisition terms also give Malin an option to increase its shareholding in Wren Therapeutics to 67%."

The acquisition terms also give Malin an option to increase its shareholding in Wren Therapeutics to 67%.

Eli Lilly and Company has reached an agreement to acquire a biopharmaceutical company named CoLucid Pharmaceuticals with the aim of enhancing its existing portfolio in migraine pain management and adding a potential near-term launch to its late-stage pipeline.

The acquisition is being executed through a tender offer and includes a purchase consideration of up to $960m.

Both companies involved in the acquisition are based in the US. The transaction is expected to be completed by the end of the first quarter of 2017.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now